Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Desmoglein-2
(
DSG2
) is an integral component of desmosomes, maintaining cell-cell adhension in multiple cancers. It has been well studied in epithelial cells, cardiomyocytes and primary prostate cancer,
colon cancer
, skin squamous cell carcinoma, except for cervical cancer. Hence, we performed this study to examine the function of
DSG2
in cervical cancer. We used TCGA and Oncomine databases to assess the expression level of
DSG2
in cervical cancer cases. Kaplan-Meier method with log-rank test was utilized to plot overall survival (OS) curve. The reverse transcription-quantitative polymerase chain reaction (qRT-PCR) and western blotting were performed to detect the expression of
DSG2
in cells. Cell Counting Kit-8 (CCK-8), wound-healing analysis, and transwell assay were carried out to examine proliferation, migration, and invasion of cells. A higher level of
DSG2
in cervical cancer was associated with lower OS rate. Knockdown of
DSG2
inhibited cervical cancer cell proliferation, migration, and invasion, while
DSG2
enhancement promoted cell proliferation, migration, and invasion. Moreover, the proteins expression of p-MEK and p-ERK that are required for mitogen-activated protein kinases (MAPK) pathway were downregulated after reducing
DSG2
. In conclusion, these findings illustrated the importance of
DSG2
in cervical cancer development and cell behaviors by mediating MAPK signaling pathway, suggesting
DSG2
maybe a novel therapeutic target in control of cervical cancer.
...
PMID:Significance of desmoglein-2 on cell malignant behaviors via mediating MAPK signaling in cervical cancer. 3193 Jul 74
